4.7 Article

Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 42, Issue 4, Pages 864-875

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2016.175

Keywords

-

Funding

  1. National Institute of Mental Health [R01MH082802, R21MH081099, 1R01MH101890, R01MH100616, 1R01MH107183]
  2. American Foundation for Suicide Prevention [SRG-XXXX-001778-1209]

Ask authors/readers for more resources

Major depressive disorder (MDD) is predicted to be the second leading cause of global disease burden by 2030. A large number of MDD patients do not respond to the currently available medication because of its poorly understood etiology. Recently, studies of microRNAs (miRNAs), which act as a molecular switch of gene expression, have shown promise in identifying a molecular network that could provide significant clues to various psychiatric illnesses. Using an in vitro system, a rodent depression model, and a human postmortem brain, we investigated the role of a brain-enriched, neuron-specific miRNA, miR-124-3p, whose expression is highly dysregulated in stressed rodents, and identified a set of target genes involved in stress response and neural plasticity. We also found that miR-124-3p is epigenetically regulated and its interaction with the RNA-induced silencing complex (RISC) is compromised in MDD. Using blood serum, we found similar dysregulation of miR-12A-3p in antidepressant-free MDD subjects. Altogether, our study demonstrates potential contribution of miR-124-3p in the pathophysiology of MDD and suggests that this miRNA may serve as a novel target for drug development and a biomarker for MDD pathogenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available